Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Scancell Holdings plc
  6. News
  7. All News
    SCLP   GB00B63D3314

SCANCELL HOLDINGS PLC

(SCLP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about SCANCELL HOLDINGS PLC
10/19Scancell Holdings plc Expands Its R&D Capabilities with New Facilities at the Oxford Sc..
CI
10/05Scancell Holdings plc Announces First Subject Dosed in COVIDITY Phase 1 Clinical Trial ..
CI
08/26SCANCELL : Shares Climb After UK Government Greenlights Cancer Treatment Trial
MT
08/26Scancell Holdings plc Announces the UK's Medicines and Healthcare Products Regulatory A..
CI
07/29Scancell Holdings plc Announces South African Health Products Regulatory Authority Appr..
CI
07/28Scancell Holdings plc Announces Executive Changes
CI
07/28Scancell Holdings plc Appoints Lindy Durrant as CEO
CI
06/22SCANCELL : COVIDITY programme to start Phase I in H221
PU
06/22SCANCELL : to Start Trial for Novel Bivalent COVID-19 Vaccine in UK, South Africa; Shares ..
MT
06/22Scancell Holdings plc Announces COVIDITY Phase 1 Clinical Trial Planned in South Africa..
CI
05/06PRESS RELEASE : Evotec launches 'beLAB1407' to accelerate translational research from the ..
DJ
02/03Scancell Holdings plc Announces an Update on its SCIB2 Clinical Development Partnership..
CI
01/29SCANCELL : H121 results highlight shift to delivery and execution January 2021
PU
01/29SCANCELL : Interim Report 31st October 2020
PU
01/29SCANCELL : Earnings Flash (SCLP.L) SCANCELL Reports Interim EPS GBX-0.71
MT
01/29Scancell Holdings plc Reports Earnings Results for the Half Year Ended October 31, 2020
CI
2020UPDATE : Scancell Climbs 15% as It Selects COVID-19 Vaccine Candidate for Development, Cli..
MT
2020SCANCELL : Selects COVID-19 Vaccine Candidate for Development, Clinical Trials
MT
2020SCANCELL : Redmile funding releases the brakes
PU
2020SCANCELL : Stock Dips 10% As It Appoints New Chief Medical Officer
MT
2020Scancell Holdings plc Appoints Gillies O'Bryan-Tear as Chief Medical Officer and Robert..
CI
2020SCANCELL : Notice of Annual General Meeting November 2020
PU
2020SCANCELL : Annual Report 30th April 2020
PU
2020Scancell Holdings plc Reports Earnings Results for the Full Year Ended April 30, 2020
CI
2020Scancell Holdings plc announced that it expects to receive ú17.900748 million in fundin..
CI
2020Cobra Biologics and Scancell Holdings plc Announces Collaboration to Manufacture COVID-..
CI
2020SCANCELL : Material fund raise means clinical progress in sight
PU
2020SCANCELL : Reasons to be cheerful May 2020
PU
2020SCANCELL : COVID 2nd generation vaccine opportunity is all upside May 2020
PU
2020SCANCELL : to Present at Three Research Conferences
PU
2020Scancell Holdings plc Announces Approval of SCIB1 Investigational New Drug Application
CI
2020Scancell Holdings plc Reports Earnings Results for the Half Year Ended October 31, 2019
CI
2020Scancell Holdings plc Signs Collaboration and Non-Exclusive Research Agreement with Uni..
CI
2019Scancell Holdings plc Signs Second Collaboration and Non-Exclusive Research Agreement w..
CI
2019Scancell Holdings plc Announces Board Changes
CI
2019Scancell Holdings plc Announces First Collaboration Agreement for AvidiMabÖ
CI
2019Scancell Holdings plc Reports Earnings Results for the Full Year Ended April 30, 2019
CI
2019Scancell Holdings plc Announces the Initiation of and Further Updates on the SSCIB1 Pha..
CI
2019Scancell Holdings plc Announces the Appointment of Martin Diggle to the Company's Board..
CI
2019Scancell Holdings PLC and Cancer Research UK Provide an Update on SCIB2
CI
2019Scancell Holdings plc Provides an Update on Progress Towards Initiating the Modi-1 Phas..
CI
2019Scancell Holdings plc Announces UK Regulatory Approval to Start SCIB1 Phase 2 Trial in ..
CI
2019Scancell Holdings plc Strengthens IP Portfolio
CI
2019Scancell Holdings plc Announces Unaudited Consolidated Earnings Results for the Six Mon..
CI
2019Scancell Holdings plc Appoints Heads of Research and Manufacturing
CI
2018Scancell Holdings plc Announces Audited Final Consolidated Earnings Results for the Ful..
CI
2018Scancell Holdings To Explore Additional Funding Options
CI
2018Kate Cornish-Bowden to Step Down as Non-Executive Director of Scancell Holdings Plc, Ef..
CI
2018Scancell Holdings plc Extends Strategic Research Collaboration with the Rheumatology Un..
CI
2018GrScancell Holdings Announces Grant of European Patent for its Moditope« Immunotherapy ..
CI
2018SCANCELL : Results of the Placing and Subscription
PU
2018SCANCELL : presents at Calculus Investor Forum
PU
2018ISA Pharmaceuticals and Scancell enter collaboration agreement for the manufacturing, d..
CI
2018SCANCELL : a member of team shortlisted for Cancer Research UK's Grand Challenge Award
PU
2018SCANCELL : Announcement of Share Options 1 February 2018
PU
2018Scancell Holdings plc Announces Unaudited Consolidated Earnings Results for the Six Mon..
CI
2018Scancell Holdings plc Announces Executive Changes
CI
2018Scancell Holdings plc Enters into Research Collaboration Agreement with Biontech
CI
2018SCANCELL : to collaborate with BioNTech
PU
2017SCANCELL : appoints Dr Cliff Holloway as Chief Executive Officer
PU
2017Scancell Holdings plc Announces Executive Changes
CI
2017Scancell Holdings PLC Reports Audited Consolidated Earnings Results for the Year Ended ..
CI
2017Oncimmune Holdings plc and Scancell Holdings plc Announces Presentation of Data on Use ..
CI
2017SCANCELL : Continued progress on SCIB1 – eight patients reach 5 year survival milest..
PU
2017Scancell Holdings plc Provides Update on SCIB1
CI
2017SCANCELL : DNA ImmunoBody« Patent Granted in Europe
PU
2017SCANCELL : Proposed placing to raise up to ú5.0 million
PU
2017Scancell Holdings plc Announces Change of Registered Office
CI
2017SCANCELL : to present at the Immuno-Oncology Summit Europe 2017
PU
2017Scancell Holdings PLC Announces Unaudited Consolidated Earnings Results for the Six Mon..
CI
2017SCANCELL : ALCII - Scancell Collaboration in Lung Cancer
PU
2016SCANCELL : preparing SCIB2 for clinical study in lung cancer
PU
2016Scancell Holdings plc Intentions to Develop its SCIB2 ImmunoBody« for the Treatment of ..
CI
2016Scancell Holdings PLC Announces Consolidated Earnings Results for the Year Ended April ..
CI
2016SCANCELL : Dr Alan J. Lewis appointed as Non-Executive Director
PU
1  2Next
Upcoming event on SCANCELL HOLDINGS PLC